Outpatient Bispecific Initiation: Emerging Trends, Eligibility Criteria, and Operational Readiness

In 'Outpatient Bispecific Initiation: Emerging Trends, Eligibility Criteria, and Operational Readiness,' our panel of experts delve into the following critical question:

There's a growing, though still emerging, trend toward initiating bispecific therapy in the outpatient setting rather than inpatient. Who is doing this, under what conditions, and is it working?

Led by the moderator, the panelists examined the growing movement toward outpatient bispecific antibody initiation, noting that while some academic centers have already published real-world evidence supporting the safety of outpatient step-up dosing for carefully selected patients, large community oncology networks are actively building the infrastructure needed to scale this approach responsibly across a broad geographic footprint. The discussion also highlighted that the push toward outpatient initiation is not limited to multiple myeloma, with bispecific antibodies rapidly expanding across solid tumor and non-oncology indications, making proactive infrastructure investment now a strategic imperative for oncology pharmacy teams that are likely to become the default administrators of these therapies for patients well beyond the hematology population. The panelists emphasized that the key to successful outpatient bispecific programs is not reacting to approvals after the fact, but rather building eligibility frameworks, formulary navigator tools, and clinical escalation pathways in advance. This will ensure that when new agents and new indications arrive, institutions are positioned to implement them thoughtfully and safely.

Throughout the conversation, the experts provide a comprehensive reflection on the field and the factors that may shape how clinicians approach care moving forward.

In the final episode, 'From Knowledge to Action: Final Takeaways for Oncology Pharmacists Implementing Bispecific Therapy,' panelists will share their closing reflections and the single most important thing they want every oncology pharmacist watching this program to walk away from and do differently, offering practical, immediately actionable guidance on bispecific antibody implementation grounded in their collective real-world experience across academic and community oncology settings.